Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a ...

Lagging behind the PD-1xVEGF leaders, Crescent has strengthened its hand by licensing Kelun’s integrin beta-6 ...

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, ...

MRK banks on Capvaxive, Winrevair and other new launches to counter Keytruda's looming 2028 LOE and record long-term growth.

BioNTech stock is a "Strong Buy", driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. Read ...

More than one-third of U.S. adults diagnosed with metastatic HER2-negative breast cancer in 2023 did not undergo testing for BRCA mutations, according to a retrospective analysis.Less than half ...

Gastric Cancer Diagnostics Market size was valued at US$ 3.5 Bn in 2024 and is projected to reach US$ 6.9 Bn by 2035, growing at a CAGR of 6.4% during 2025–2035.

Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell lung cancer. The OptiTROP-Lung05 study is the first phase 3 trial of an ...

The U.S. FDA assigned a target action date of April 8, 2026PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #FDA--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA ...

"Kelun-Biotech’s ADC plus Keytruda touts first-line success in late-stage NSCLC" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.